ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“ESMOTAT25: The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine.
Vivek Subbiah, MD discusses the paradigm shift away, at least partially, from organ-based treatment to molecularly guided treatment across tumour types. He describes how regulatory shifts and greater access to tumour profiling are now needed to realise their full benefits for patients.
To learn more, read the Opinion piece in the ESMO Daily Reporter.”
More posts featuring ESMO.